PARP1 and ovarian carcinoma: Furthermore, in-depth studies on HRD biomarkers could help more accurately identify patients who are likely to benefit from PARP inhibitor therapy (Figure 3: Efficacy of Targeted Therapies in Ovarian Cancer).